Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavacamten - Bristol Myers Squibb

Next Previous
Drug Profile

Mavacamten - Bristol Myers Squibb

Alternative Names: BMS-986427; Camzaios; CAMZYOS; Camzyos; HCM 1; MAVA-Bristol Myers Squibb/Myokardia; MYK 461; SAR-439152

Latest Information Update: 09 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MyoKardia
  • Developer Bristol-Myers Squibb; LianBio; MyoKardia
  • Class Cardiovascular therapies; Ethylamines; Heart failure therapies; Pyrimidinones; Small molecules
  • Mechanism of Action Cardiac myosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypertrophic cardiomyopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertrophic cardiomyopathy
  • Phase II Heart failure

Most Recent Events

  • 29 Mar 2026 Updated efficacy and adverse events data from a phase III trial in Hypertrophic cardiomyopathy released by Bristol Myers Squibb
  • 16 Jan 2026 MyoKardia completes phase-II/III MAVA-LTE trial Hypertrophic cardiomyopathy in USA, Belgium, Czech Republic, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain and United Kingdom (PO) (NCT03723655)
  • 12 Jan 2026 Efficacy and adverse events data from a phase III trial in Hypertrophic cardiomyopathy released by Bristol Myers Squibb

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top